ARG1 and head and neck squamous cell carcinoma: Treatment with the Arg1 inhibitor nor-NOHA abrogated MDSC-mediated T cell suppression experimentally [34, 36], and restored the proliferation of MDSC-suppressed lymphocytes from patients with multiple myeloma or head and neck squamous cell carcinoma (HNSCC) [37].